Eltrombopag and liver function in ITP patients
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at how the drug eltrombopag affects the liver in people with primary ITP (immune thrombocytopenic purpura), a condition where the immune system destroys platelets. It aims to check if liver problems develop during treatment and who might be at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary ITP (immune thrombocytopenic purpura).
- You are currently taking or about to start eltrombopag as part of your treatment.
- Your liver function tests at the start of the study were normal.
- You may or may not have diabetes or fatty liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called thrombopoietin agonists to help increase platelet counts in people with idiopathic thrombocytopenic purpura (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. The goal is to see if this treatment is safe and effective for adults with ITP.
This trial tests adding a new drug (ripertamab) to a standard ITP treatment (eltrombopag) for patients whose platelet count hasn't improved with steroids. The goal is to see if the combination works better at raising platelet counts and lowering bleeding risk.
This trial tests a combination of two drugs—avatrombopag and all-trans retinoic acid—in adults with persistent or chronic immune thrombocytopenia (ITP) whose platelet levels stay low despite prior treatments. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.